Whitehawk Therapeutics Inc. has released a corporate presentation detailing its advancements in antibody-drug conjugate $(ADC)$ technology. The company's pipeline features three ADC assets, including HWK-007 targeting PTK7 and HWK-016 targeting MUC16, both expected to enter Phase 1 clinical trials with indications across several cancer types such as non-small cell lung, ovarian, endometrial, and mesothelioma. The presentation highlights the novel linker-payload technology utilized in Whitehawk's ADC platform, which is designed for enhanced potency, stability, and safety compared to average topoisomerase I inhibitor ADCs. Preclinical data show greater tumor potency, improved stability in circulation, and a higher safety margin in animal models. As of September 30, 2025, Whitehawk reported $162.6 million in cash, with an anticipated runway into 2028. Key investors include Kalehua and Ally Bridge Group. You can access the full presentation through the link below.